Nyxoah
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | <1m | <1m | 3.1m | 4.3m | 8.8m | 36.2m | 87.0m |
% growth | - | 1135 % | 262 % | 41 % | 102 % | 312 % | 141 % |
EBITDA | (11.4m) | (22.6m) | (25.7m) | (41.2m) | (55.8m) | (67.6m) | (64.9m) |
% EBITDA margin | (16483 %) | (2649 %) | (835 %) | (947 %) | (636 %) | (187 %) | (75 %) |
Profit | (12.2m) | (27.6m) | (31.2m) | (43.2m) | (55.2m) | (62.8m) | (54.8m) |
% profit margin | (17746 %) | (3242 %) | (1012 %) | (994 %) | (628 %) | (174 %) | (63 %) |
EV / revenue | 5055.1x | 562.7x | 43.1x | 16.8x | 24.3x | 7.6x | 4.0x |
EV / EBITDA | -30.7x | -21.2x | -5.2x | -1.8x | -3.8x | -4.1x | -5.3x |
R&D budget | 2.9m | 6.0m | 15.9m | 27.7m | - | - | - |
R&D % of revenue | 4217 % | 699 % | 514 % | 636 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€8.0m | Series A | ||
€50.0k | Grant | ||
* | €18.0m | Series B | |
* | €15.0m | Series C | |
€25.0m | Series C | ||
N/A | N/A | IPO | |
N/A | N/A | IPO | |
* | N/A | $45.9m | Post IPO Equity |
* | €37.5m | Post IPO Debt | |
Total Funding | €66.1m |
Recent News about Nyxoah
EditNyxoah is a medical technology startup focused on providing innovative solutions for patients suffering from moderate to severe Obstructive Sleep Apnea (OSA). The company has developed a user-friendly, comfortable, and efficient treatment that allows individuals to enjoy restful sleep and improve their quality of life. The core product involves a nightly patch applied under the chin, which stimulates the hypoglossal nerve to keep the airway open, thereby reducing the symptoms of OSA such as snoring and interrupted breathing.
Nyxoah primarily serves patients diagnosed with OSA, a condition characterized by repeated interruptions in breathing during sleep due to the relaxation of throat muscles. The company also collaborates with healthcare professionals who diagnose and recommend treatments for sleep apnea. The market for Nyxoah's products includes individuals seeking non-invasive, effective solutions for sleep apnea, as well as medical practitioners looking for reliable treatment options for their patients.
The business model of Nyxoah revolves around the sale of its sleep apnea treatment devices. The company generates revenue by selling these devices directly to consumers and through partnerships with healthcare providers. By offering a subscription-based model for the nightly patches, Nyxoah ensures a steady stream of recurring revenue. Additionally, the company may engage in licensing agreements and collaborations with other medical technology firms to expand its market reach.
In summary, Nyxoah is a promising player in the medical technology sector, addressing a significant health issue with a novel and effective solution. The company's focus on patient comfort and ease of use, combined with its innovative approach to treating OSA, positions it well in the growing sleep apnea treatment market.
Keywords: Sleep Apnea, Medical Technology, Hypoglossal Nerve, Treatment Device, Patient Comfort, Healthcare, Non-Invasive, Recurring Revenue, Innovation, Quality of Life.